Do GLP-1 Supplements Actually Work? What the Evidence Shows

Short answer: no over-the-counter “GLP-1 supplement” has been shown in any peer-reviewed trial to produce weight loss close to what prescription GLP-1 drugs produce. Products marketed as GLP-1 supplements do not contain semaglutide, tirzepatide, or any pharmaceutical GLP-1 receptor agonist, and none is FDA-approved for weight loss — a point even a supplement retailer’s own guide concedes ^[6]. The FDA has separately warned that some weight-loss products marketed as supplements may contain hidden drug ingredients and may be falsely advertised as natural, so “no drug on the label” is not the same as a guarantee of what is in the bottle ^[5]. Some individual ingredients — fiber above all — have modest supporting evidence, but the finished products marketed as “GLP-1 boosters” or “nature’s Ozempic” are riding a wave of drug-industry demand, not proven results.

That wave is large and growing. One market-research vendor, Straits Research, estimates the global GLP-1 supplement market at USD 2 billion in 2025, rising to USD 2.24 billion in 2026 and a projected USD 5.53 billion by 2034, at an 11.97% compound annual growth rate — vendor projections, not audited sales ^[1]. A separate firm, Fact.MR, sizes the overlapping “GLP-1 companion products” market at about USD 4.7 billion in 2025, roughly USD 5.2 billion in 2026, and USD 14.4 billion by 2036, at a CAGR of around 10.7% ^[2]. The two firms count differently, so the numbers do not match — but both point the same direction.

How big is this market, and why is it growing so fast?

The demand driver is prescription drugs, not supplements. A study in the Annals of Internal Medicine, drawing on 45 million de-identified medical records, found a 700% rise in GLP-1 prescriptions for patients with overweight or obesity over four years — about 21,000 US patients in 2019 versus 174,000 in 2023 ^[3]. J.P. Morgan Research estimates the GLP-1 drug market will exceed $100 billion by 2030 ^[3].

Straits Research puts North America at 41.32% of the supplement market in 2025, with the US segment alone at USD 735.75 million in 2025 ^[1]. Fact.MR’s companion-products breakdown for 2026: high-protein nutrition at 31.9%, powders at 24.8%, and home consumption at 35.8% ^[2]. Retailers have noticed — US pharmacy chains and wellness retailers have added dedicated “GLP-1 support” shelf sections and online filtering categories ^[1], and The Vitamin Shoppe launched a telehealth service in May 2024 that pairs prescription weight-loss drugs with supplements and lifestyle guidance ^[3].

Are all “GLP-1 supplements” the same product?

No — the keyword hides two different categories, and mixing them up is where most confusion starts.

Larisa Pavlick, regulatory program manager of Market Integrity at Informa Markets and a former FDA investigator, says GLP-1 supplements introduced in the industry fall into (a) nutritional support for people on GLP-1 drugs, and (b) products claiming to “mimic the pharmaceutical-like effect” of those drugs. The second category, she says, is “where we dive into some potential for adulteration” ^[3]. Her interview was published by SupplySide Supplement Journal, an outlet the source notes is owned by Informa Markets — the same company that employs her — a relationship worth knowing when weighing her framing ^[3].

A guide from YourHealthier, a supplement retailer that sells its own GLP-1 companion product, describes the two lanes this way ^[6]. GLP-1 boosters are aimed at people not on a prescription. They typically contain prebiotic fiber, probiotics, berberine, chromium, 5-HTP, or saffron extract, and are marketed as “natural GLP-1 support” ^[6].

GLP-1 companion formulas are for people already on Ozempic, Wegovy, Mounjaro, or Zepbound. They contain things like vitamin D, B12, iron, magnesium, electrolytes, protein, or ginger, and they do not claim to raise GLP-1 at all — they claim to fill nutritional gaps left by eating much less food ^[6].

Again, per that retailer’s guide: neither category contains semaglutide, tirzepatide, or any GLP-1 receptor agonist, and neither is FDA-approved for weight loss ^[6].

How much weight do people lose on the prescription drugs?

To judge any supplement claim, you need the benchmark. A once-weekly GLP-1 receptor agonist injection produces roughly 14.9–20% weight loss, compared with about 5–7% from traditional diet and lifestyle change alone, according to a narrative review whose authors are employed by GNC, a supplement retailer ^[4]. Across phase 3 trials, prescription GLP-1 receptor agonists produce 7–24% body-weight loss, a figure cited in a 2025 joint advisory attributed to ACLM, ASN, OMA, and TOS and repeated in a supplement retailer’s guide ^[6]. The drugs work by stimulating insulin production, delaying gastric emptying, and reducing hunger ^[3]. The class now also includes an oral small-molecule GLP-1 agonist, orforglipron (Foundayo, Eli Lilly) ^[5].

No OTC finished product has been shown in a peer-reviewed trial to replicate that loss ^[6].

Is berberine really “nature’s Ozempic”?

Berberine is the ingredient most heavily promoted with that phrase, and the evidence does not support the comparison. NCCIH (the National Center for Complementary and Integrative Health) notes that some small studies link berberine to modest weight or waist-circumference reductions in people with obesity or metabolic conditions, but the evidence is limited and short term ^[7]. Unlike semaglutide, berberine has not been shown in large, long-term trials to reduce cardiovascular events or complications of obesity ^[7].

On lipids, one systematic review and meta-analysis found reductions in total cholesterol, LDL cholesterol, and triglycerides — but the authors noted high clinical heterogeneity and generally low methodological quality among the included trials, so the findings need cautious interpretation ^[5].

One more wrinkle: berberine was first isolated in 1917 from goldenseal, and very little berberine is absorbed from whole goldenseal, so research on the isolated compound does not necessarily transfer to whole-plant products ^[7].

What about chromium, green tea extract, resveratrol, and probiotics?

Each has a sliver of evidence. None of it amounts to a drug substitute.

Chromium picolinate: a meta-analysis in patients with diabetes found improved glycemic control without a significant increase in adverse events versus placebo — but that evidence is about blood sugar in diabetes, not weight loss ^[5].

Green tea extract: a Cochrane review found a small, statistically nonsignificant weight loss in adults with overweight or obesity, judged unlikely to be clinically meaningful ^[5].

Resveratrol: human weight-loss evidence is inconsistent, with substantial heterogeneity across trials in dose, duration, delivery method, participants, and outcomes ^[5].

Probiotics: a 2024 systematic review found a trend toward preventing weight gain and reducing body weight in people with excess weight, with Lactobacillus and Bifidobacterium combinations appearing most effective — but effects from one strain or combination cannot be generalized to all probiotic products ^[5].

Is fiber the one ingredient worth taking seriously?

Fiber — glucomannan, psyllium, inulin — may be the most clinically reasonable ingredient to discuss as an adjunctive, nonprescription option, in the words of one pharmacist-authored clinical article, though explicitly not as a GLP-1 substitute ^[5]. In one randomized controlled study of adults with overweight or obesity and traits of metabolic syndrome, fiber supplementation combined with energy restriction improved body weight, BMI, fat mass, visceral fat, lipid profile, and inflammatory markers ^[5].

That is a real result, but note what it is: fiber plus calorie restriction, in a trial of a mechanism, not a branded “GLP-1 booster” product. And per a supplement retailer’s guide, generic prebiotic fiber delivers that mechanism for far less money than branded boosters ^[6].

Could a “GLP-1” supplement contain hidden drug ingredients?

Products marketed as GLP-1 supplements do not list or claim to contain semaglutide, tirzepatide, or any pharmaceutical GLP-1 receptor agonist, per the guide from YourHealthier, a retailer that sells a GLP-1 companion product and has a commercial stake in how the category is framed ^[6]. But “sold as a supplement” is not itself a guarantee of contents: the FDA has warned that weight-loss products marketed as supplements may contain hidden drug ingredients and may be falsely advertised as natural ^[5]. Pavlick, the former FDA investigator, points to products claiming to mimic pharmaceutical effects as the category with “potential for adulteration,” and she notes that weight loss is one of five supplement categories the FDA watches “pretty closely” because of a higher incidence of adulteration in those products ^[3].

If I’m already on Ozempic or Wegovy, do I actually need supplements?

This is where the evidence is strongest — and it is about nutrition, not about boosting GLP-1. GLP-1 receptor agonists slow gastrointestinal transit and suppress appetite, which displaces nutrient intake; nausea and vomiting skew food choices; and skeletal muscle loss is the bigger concern ^[4]. GLP-1 therapy typically cuts daily energy intake by 16–39%, per the supplement retailer’s guide ^[6].

A 2026 review by Urbina et al. in Clinical Obesity covering 480,825 adults — as summarized by the same retailer, YourHealthier — found vitamin D deficiency in 13.6% of users by 12 months, ferritin 26–30% lower, more than 60% of users below requirements for calcium and iron, and vitamin D intake averaging about 20% of recommendations ^[6]. Harvard Health’s summary of the same review, as reported by that guide, noted nutritional-deficiency anemia in 4% of the study population within a year ^[6].

A narrative review on supplementation during GLP-1RA treatment — whose authors are employed by GNC, a supplement retailer, a conflict worth knowing — cites a protein intake target of 1.2–2.0 g/kg/day, notes that whey protein plus resistance training helps preserve lean mass, and points to added strength benefits from creatine monohydrate and HMB. It also suggests multivitamins for micronutrient insufficiency as determined by individual deficiencies, and fiber and probiotics for bowel regularity and side-effect management ^[4]. A 2025 joint advisory attributed to ACLM, ASN, OMA, and TOS covers nutrient adequacy during GLP-1RA treatment — fruits, vegetables, whole grains, lean protein, and legumes, while limiting refined carbohydrates, sugary drinks, and processed foods ^{[6] [4]}.

One practical caution: fibers, sugar alcohols, and protein concentrates — the very ingredients in many companion products — can worsen bloating and nausea in GLP-1 users, and full serving sizes often go unfinished ^[1].

Why isn’t the FDA stopping these claims?

Because supplements are regulated under DSHEA, they require no pre-market efficacy testing, as the supplement retailer’s guide notes ^[6]. Enforcement has been sparse: as of May 2025, the FDA had issued exactly one warning letter over GLP-1 supplement claims — on December 10, 2024, to Veronvy for its “Elily Veronvy” and “Elily Veronvy 40+” products ^[3]. The FDA treated those products as unapproved new drugs under the FDCA because they were intended to prevent, treat, or cure disease and/or affect the structure or function of the body ^[3]. The company had claimed its products were better than Ozempic, FDA-approved, and clinically proven, with extreme weight-loss claims and before-and-after photos ^[3].

Asa Waldstein, principal of the regulatory firm Supplement Advisory Group, says “supports GLP-1” structure-function framing has largely escaped warning letters, while “GLP-1 agonist” claims likely cross the compliance line — and risk rises further when combined with phrases like “nature’s Ozempic” or “helps with nausea” ^[3]. Katie Bond, a partner at law firm Keller and Heckman, says an FDA rule prohibits claiming a supplement increases the effectiveness of a drug ^[3]. Theodora McCormick, a shareholder at law firm Baker Donelson, advises brands to avoid claims that a product can treat diabetes or obesity, noting the FDA considers obesity a disease ^[3]. The FTC declined to provide a comment for the article that reported on this enforcement gap, and attorney Marc Ullman predicted limited Bureau of Consumer Protection activity ^[3]. Meanwhile, online marketplaces and wellness retailers have increased monitoring of GLP-1 labeling and promotional terminology on their own ^[1].

Are GLP-1 supplements safe?

“Not a drug” does not mean “no risks.” The main concerns are side effects and interactions.

Berberine’s common side effects include stomach pain or cramps, diarrhea or constipation, gas, bloating, and nausea or vomiting, with transaminase elevation reported ^{[7] [5]}. More serious reports include dizziness or fainting, low blood pressure, slow heart rate, abnormal heart rhythms, and allergic reactions ^[7]. NCCIH flags high-risk groups: infants and newborns, pregnancy and breastfeeding, severe liver or kidney disease, heart rhythm problems, and very low blood pressure ^[7]. Berberine affects liver enzymes CYP2D6, CYP3A4, and CYP2C9 and drug transporters, and its possible interaction concerns include diabetes medicines, blood pressure and heart drugs, statins, warfarin, sedating drugs, and cyclosporine ^[7].

Chromium alongside insulin or other glucose-lowering therapy carries a risk of additive glucose lowering ^[5]. Resveratrol has dose-related adverse effects, possible cytochrome P450 interactions, warfarin bleeding risk, and diarrhea and nausea at high doses ^[5]. Green tea extract carries a hepatotoxicity concern, especially with concentrated extracts, plus caffeine effects like insomnia and palpitations ^[5]. Fiber can cause bloating, flatulence, diarrhea, or constipation; it requires adequate water and should be separated from other medications to avoid impairing their absorption ^[5]. Probiotics warrant caution in immunocompromised people or those with significant underlying illness ^[5].

What’s worth the money and what isn’t?

For someone not on a prescription who wants a nonprescription option, fiber is the ingredient a pharmacist-authored article calls possibly the most clinically reasonable — and, per the supplement retailer’s guide, generic prebiotic fiber delivers the same mechanism for a fraction of branded booster pricing ^{[5] [6]}.

Product type	Typical monthly cost	What you’re paying for
Branded GLP-1 booster	$25–60 [6]	Fiber, probiotics, or botanicals under a “GLP-1” label
Generic prebiotic fiber	$8–15 [6]	The same satiety mechanism without the branding [6]

Those prices come from YourHealthier, a retailer that sells a companion product and does not sell boosters — a commercial position worth weighing when reading its pricing advice ^[6].

For someone already on a GLP-1 drug, the same retailer frames the priority order as protein and resistance training first, with creatine, magnesium, electrolytes, and vitamins tied to tested deficiencies second ^[6] — an ordering from a company with a stake in the category, not a clinical guideline. Companion products should be bought for nutrient support, not to alter the drug’s effect ^[3]. A pharmacist’s framing is useful here: the question is less “does it work?” and more “is it appropriate and safe for this patient?” ^[5].

What should I check before buying anything labeled “GLP-1”?

A short checklist, built from what regulators and pharmacists actually look at:

• Is the cited outcome a biomarker or actual weight change? A rise in some measured level is not the same as pounds lost ^[6].
• Is there a trial on the finished product, or just on individual ingredients? Ingredient studies do not validate the branded blend ^[6].
• Does it make disease claims — treating diabetes or obesity? McCormick notes the FDA considers obesity a disease, and such claims make the product an unapproved new drug ^[3].
• Does it use “clinically proven,” “FDA-approved,” or “better than Ozempic” language? That is the exact pattern the FDA cited in its only GLP-1 supplement warning letter ^[3].
• Have you checked interactions with current medicines, pregnancy status, liver or kidney disease, diabetes history, anticoagulant use, or immunocompromise? ^[5]
• Do you know that supplement quality varies? Pharmacists are specifically trained to counsel on this variability ^[5].

One final note: nothing here is medical advice, and no supplement decision should be made without talking to a prescriber or pharmacist — especially if you are already taking a GLP-1 medication or being treated for diabetes, heart disease, or another chronic condition. Waldstein cautions that because Ozempic is indicated for diabetes and heart disease, there may be serious health issues if a consumer foregoes medical treatment in search of a natural remedy ^[3].

Sources

1. Straits Research. GLP-1 Supplement Market Size, Share & Trends Analysis Report, 2026-2034. August 24, 2026.
2. Fact.MR. GLP-1 Companion Products Market, Global Market Analysis Report - 2036. May 20, 2026.
3. SupplySide Supplement Journal. Regulators mostly silent on GLP-1 supplement claims.
4. PubMed Central. Dietary supplement considerations during glucagon-like Peptide-1 receptor agonist treatment: A narrative review.
5. Contemporary Clinic. GLP-1 Boosters: Responding to Supplement Marketing Claims and Safety Questions.
6. YourHealthier. Best GLP-1 Supplements 2026: Boosters vs Companion Vitamins.
7. Drugs.com. What is berberine used for? February 26, 2026.
8. Dr Brad Stanfield. Chromium: Benefits, Forms, Dosing, and Side Effects.
9. Nature Medicine. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. July 2019.
10. Nature Medicine. Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial. June 2026.
11. PubMed Central. The Positive Effects of Yerba Maté (Ilex paraguariensis) in Obesity.
12. Obesity. A Systematic Review of Dietary Supplements and Alternative Therapies for Weight Loss. July 2021.
13. Carolina Population Center, University of North Carolina at Chapel Hill. Review shows minimal, high-quality evidence dietary supplements lead to weight loss. June 23, 2021.
14. Ro. GLP-1 patches: do they work? Plus, other non-injectable alternatives. February 5, 2026.
15. Baptist Health. What Are GLP-1 Patches? A Helpful Overview. December 18, 2025.
16. Drugs.com. Do GLP-1 patches work? No FDA approval, no proven benefit. April 30, 2026.
17. PBS News. In the gray world of GLP-1 supplements online, health experts urge caution.
18. Federal Trade Commission. Penalty Offenses Concerning Weight Loss.
19. SupplySide Supplement Journal. ‘Clinically proven’ claims are out: National Advertising Division recommendations on Tru Niagen upheld.
20. SupplySide Supplement Journal. Class action targets Kardashian GLP-1 supplement. June 10, 2025.
21. ClassAction.org. Lemme Lawsuit Claims GLP-1 Weight Loss Capsules Not as Effective as Advertised.
22. Global Cosmetics News. Lemme Faces New Class-Action Lawsuit Over GLP-1 Supplement Marketing Claims. July 22, 2026.
23. US Food and Drug Administration. Questions and Answers about FDA’s Initiative Against Contaminated Weight Loss Products.
24. ConsumerLab.com. Latest Information About Berberine: Product Reviews, Warnings, Recalls, & Clinical Updates.
25. Science Media Centre. Expert reaction to an RCT on the use of pasteurized Akkermansia muciniphila MucT for weight loss maintenance after an 8-week low-energy diet. May 12, 2026.
26. PubMed Central. Medical research article.
27. PacerMonitor. Robins v. Lemme Inc. (1:25-cv-01938), New York Southern District Court. March 9, 2025.
28. US Food and Drug Administration. FDA Roundup: December 17, 2024. December 17, 2024.
29. Federal Trade Commission. Press release on weight loss patch manufacturer banned from selling weight loss patches. August 2007.
30. PubMed. Once-Weekly Semaglutide in Adults with Overweight or Obesity.